Arance AM et al. Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase 3 IMspire170 trial. Proc ESMO 2019;Abstract LBA69.
Ascierto PA et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med 2019;25(6):941-6. Abstract
Ascierto PA, Eggermont AMM. Neoadjuvant therapy in melanoma: The next step? Lancet Oncol 2018;19(2):151-3. Abstract
Carlino MS et al. Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study. ASCO 2019;Abstract TPS9596.
Da Silva IEDP et al. Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy. ASCO 2019;Abstract 9511.
Drago JZ et al. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: A real-life multicenter study. Melanoma Res 2019;29(1):65-9. Abstract
Dummer R et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018;19(5):603-15. Abstract
Dummer R et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial. Lancet 2018;19(10):1315-27. Abstract
Eggermont AMM et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378:1789-801. Abstract
Eggermont AMM et al. Combination immunotherapy development in melanoma. Am Soc Clin Oncol Educ Book 2018;38:197-207. Abstract
Gonzalez M et al. A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial). ASCO 2019;Abstract TPS9600.
Hauschild A et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol 2018;[Epub ahead of print]. Abstract
Hodi FS et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19(11):1480-92. Abstract
Larkin JMG et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO + IPI) combination therapy in advanced melanoma. ESMO 2019;Abstract LBA68_PR.
Long GV et al. Long-term outcomes from the randomized ph 2 study of nivolumab (nivo) or nivo + ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC). Proc ESMO 2019;Abstract 1311O.
Luke JJ et al. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: A real-world study. Future Oncol 2019;15(25):2933-42. Abstract
Nathan PD et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. ASCO 2019;Abstract 9507.
Osgood C et al. FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type. ASCO 2019;Abstract 9508.
Owen CN et al. A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy. ASCO 2019;Abstract 9502.
Pavlick AC et al. Frontline therapy for BRAF-mutated metastatic melanoma: How do you choose, and is there one correct answer? Am Soc Clin Oncol Educ Book 2019;39:564-71. Abstract
Postow MA. Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse? Clin Adv Hematol Oncol 2018;16(5):353-5. Abstract
Ribas A et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med 2019;25(6):936-40. Abstract
Robert C et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019;381(7):626-36. Abstract
Saab KR et al. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Cancer 2019;125(6):884-91. Abstract
Schadendorf D et al. Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase 2 trial (IMMUNED). ESMO 2019;Abstract LBA67.
Shoushtari AN et al. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol 2018;4(1):98-101. Abstract
Sullivan RJ et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med 2019;25(6):929-35. Abstract
Tawbi HA et al. Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). ASCO 2019;Abstract 9501.
Tawbi HA et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 2018;379(8):722-30. Abstract
Valpione S et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur J Cancer 2018;91:116-24. Abstract
Weber JS et al. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial. ESMO 2019;Abstract 1310O.